Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Basic) (2018 - 2024)

Historic EPS (Basic) for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2024 value amounting to -$0.07.

  • BioNexus Gene Lab's EPS (Basic) rose 5186.17% to -$0.07 in Q3 2024 from the same period last year, while for Sep 2024 it was -$0.07, marking a year-over-year increase of 5186.17%. This contributed to the annual value of -$0.17 for FY2023, which is 84941.36% down from last year.
  • Per BioNexus Gene Lab's latest filing, its EPS (Basic) stood at -$0.07 for Q3 2024, which was up 5186.17% from $0.01 recorded in Q2 2024.
  • BioNexus Gene Lab's EPS (Basic)'s 5-year high stood at $0.02 during Q4 2023, with a 5-year trough of -$0.16 in Q3 2023.
  • In the last 5 years, BioNexus Gene Lab's EPS (Basic) had a median value of -$0.0 in 2020 and averaged -$0.01.
  • Within the past 5 years, the most significant YoY rise in BioNexus Gene Lab's EPS (Basic) was 70948.81% (2023), while the steepest drop was 280922.1% (2023).
  • BioNexus Gene Lab's EPS (Basic) (Quarter) stood at -$0.0 in 2020, then surged by 325.5% to $0.0 in 2021, then plummeted by 192.59% to -$0.0 in 2022, then surged by 709.49% to $0.02 in 2023, then tumbled by 438.17% to -$0.07 in 2024.
  • Its EPS (Basic) stands at -$0.07 for Q3 2024, versus $0.01 for Q2 2024 and -$0.01 for Q1 2024.